HER2 Positive Gastric Carcinomas and Their Clinico-Pathological Characteristics

  • Ljubomir Ognjenovikj University Clinic of Abdominal Surgery, Faculty of Medicine, Ss Cyril and Methodius University of Skopje, Skopje
  • Gjorgji Trajkovski University Clinic of Abdominal Surgery, Faculty of Medicine, Ss Cyril and Methodius University of Skopje, Skopje
  • Stojan Gjoshev University Clinic of Abdominal Surgery, Faculty of Medicine, Ss Cyril and Methodius University of Skopje, Skopje
  • Aleksandar Shumkovski University Clinic of Abdominal Surgery, Faculty of Medicine, Ss Cyril and Methodius University of Skopje, Skopje
  • Darko Dzambaz University Clinic of Abdominal Surgery, Faculty of Medicine, Ss Cyril and Methodius University of Skopje, Skopje
  • Dragan Hadzi-Manchev University Clinic of Abdominal Surgery, Faculty of Medicine, Ss Cyril and Methodius University of Skopje, Skopje
  • Goce Volcevski
  • Igor Fildishevski University Clinic for Surgery St. Naum Ohridski, Skopje
  • Dafina Nikolova University Clinic of Gastroenterohepatology, Faculty of Medicine, Ss Cyril and Methodius University of Skopje, Skopje
  • Gordana Petrushevska Institute of Pathology, Faculty of Medicine, Ss Cyril and Methodius University of Skopje, Skopje
  • Vesna Janevska Institute of Pathology, Faculty of Medicine, Ss Cyril and Methodius University of Skopje, Skopje
  • Vlado Janevski University Clinic of Abdominal Surgery, Faculty of Medicine, Ss Cyril and Methodius University of Skopje, Skopje
Keywords: gastric cancer, HER2 expression, immunohistochemistry, TNM classification, tumour grade

Abstract

BACKGROUND: HER2 protein expression in gastric carcinoma, in correlation with existing, acknowledged prognostic factors which include the parameters that determine the TNM stage of the disease, could become the basis for ongoing research in the field of molecular targeted and personalised therapy.

AIM: To determine the expression of the HER2 protein in gastric carcinoma and to correlate the expression of a HER2 protein with clinicopathological characteristics of the disease.

MATERIAL AND METHODS: The data of HER2 protein expression and the parameters of the TNM classification were obtained from the histopathological reports of the Institute of Pathology in Skopje, and for the clinical stage we used patient’s files from the University Clinic for Abdominal Surgery in Skopje.

RESULTS: The analysis of the correlation of HER2 protein expression and TNM classification parameters pointed out a significant correlation between HER2 protein expression and intragastric localisation of gastric carcinoma (P = 0.005), and the tumour grade of differentiation (P = 0.034). There was also a positive correlation between HER2 protein expression pattern and positive lymph nodes in patients with gastric carcinoma (P = 0.03). The expression pattern of HER2 +++ was significantly more common registered in patients with positive lymph nodes (P = 0.03)

CONCLUSION: The expression of HER2 protein could represent a biological marker with prognostic and predictive value in patients with gastric carcinoma. Considering the high mortality rate in patients with gastric carcinoma and lack of international standardised therapeutic approach, research of the role and significance of HER2 overexpression and Trastuzumab therapy may prove useful in the development of new therapeutic strategies.

Downloads

Download data is not yet available.

Metrics

Metrics Loading ...

Plum Analytics Artifact Widget Block

References

Parkin DM, Bray F, Ferlay J, et al. Global cancer statistics, 2002. CA Cancer J Clin. 2005; 55:74–108. https://doi.org/10.3322/canjclin.55.2.74 PMid:15761078

Lee HE, Chae SW, Lee YJ, et al. Prognostic implications of type and density of tumour-infiltrating lymphocytes in gastric cancer. BJC. 2008; 99:1704–11. https://doi.org/10.1038/sj.bjc.6604738 PMid:18941457 PMCid:PMC2584941

Jemal A, Bray F, Center MM, et al. Global cancer statistics. CA Cancer J Clin. 2011; 61:69 90. https://doi.org/10.3322/caac.20107 PMid:21296855

Cunningham D, Allum WH, Stenning SP, et al. Perioperative chemotherapy versussurgery alone for resectable gastroesophageal cancer. New Eng J Med. 2006; 355(1):11–22. https://doi.org/10.1056/NEJMoa055531 PMid:16822992

Macdonald JS, Smalley SR, Benedetti J, et al. Chemoradiotherapy after surgerycompared with surgery alone for adenocarcinoma of the stomach or gastroesophageal junction. N Eng J Med. 2001; 345(10):725–30. https://doi.org/10.1056/NEJMoa010187 PMid:11547741

Sastre J, García-Saenz JA, Díaz-Rubio E. Chemotherapy for gastric cancer. World journal of gastroenterology: WJG. 2006; 12(2):204. https://doi.org/10.3748/wjg.v12.i2.204 PMid:16482619 PMCid:PMC4066028

Gravalos C, Jimeno A. HER2 in gastric cancer: a new prognostic factor and a novel therapeutic target. Annals of Oncology. 2008; 19:1523–29. https://doi.org/10.1093/annonc/mdn169 PMid:18441328

Zhou F, Li N, Jiang W, et al. Prognosis significance of HER 2/neu overexpression/amplification in Chinese patients with curatively resected gastric cancer after the ToGA clinical trial. World J Surg Oncol. 2012; 10:274. https://doi.org/10.1186/1477-7819-10-274 PMid:23249720 PMCid:PMC3579675

Jin Z, Jiang W, Wang L. Biomarkers for gastric cancer: Progression in early diagnosis and prognosis (Review). Oncology Letters. 2015; 9:1502-08. https://doi.org/10.3892/ol.2015.2959 PMid:25788990 PMCid:PMC4356326

Bazley LA, Gullick WJ. The epidermal growth factor receptor family. Endocrine-Related Cancer. 2005; 12:S17–S27. https://doi.org/10.1677/erc.1.01032 PMid:16113093

Schuell B, Gruenberger T, Scheithauer W, et al. HER 2/neu protein expression in colorectal cancer. BMC Cancer. 2006; 8(6):123. https://doi.org/10.1186/1471-2407-6-123 PMid:16681853 PMCid:PMC1475876

Eltze E, Wulfing C, Von Struensee D, et al. Cox-2 and Her2/neu co-expression in invasive bladder cancer. Int J Oncol. 2005; 26(6):1525–1531. https://doi.org/10.3892/ijo.26.6.1525

McKenzie SJ, DeSombre KA, Bast BS, et al. Serum levels of HER-2 neu (C-erbB-2) correlate with overexpression of p185neu in human ovarian cancer. Cancer. 1993; 71:3942–6. https://doi.org/10.1002/1097-0142(19930615)71:12<3942::AID-CNCR2820711224>3.0.CO;2-3

Hetzel DJ, Wilson TO, Keeney GL, et al. HER-2/neu expression: a major prognostic factor in endometrial cancer. Gynecol Oncol. 1992; 47:179–85. https://doi.org/10.1016/0090-8258(92)90103-P

Hirashima N, Takahashi W, Yoshii S, et al. Protein overexpression and gene amplification of c-erb B-2 in pulmonary carcinomas: a comparative immunohistochemical and fluorescence in situ hybridization study. Mod Pathol. 2001; 14:556–662. https://doi.org/10.1038/modpathol.3880350 PMid:11406656

Mitra AB, Murty VVS, Pratap M, et al. ERBB2 (HER2/neu) oncogene is frequently amplified in squamous cell carcinoma of the uterine cervix. Cancer Res. 1994; 54:637–9. PMid:7905784

Beckhardt RN, Kiyokawa N, Xi L, et al. HER-2/neu oncogene characterization in head and neck squamous cell carcinoma. Arch Otolaryngol Head Neck Surg. 1995; 121(11):1265–70. https://doi.org/10.1001/archotol.1995.01890110041008 PMid:7576473

Abrahao-Machado LF, Scapulatempo-Neto C. HER2 testing in gastric cancer: An update. World J Gastroenterol. 2016; 22(19):4619-4625. https://doi.org/10.3748/wjg.v22.i19.4619 PMid:27217694 PMCid:PMC4870069

Lordick F, Bang YJ, Kang YK, et al. HER2-positive advanced gastric cancer: similar HER2-positivity levels to breast cancer. Eur J Cancer. 2007; 5(4):271.

Kang Y, Bang Y, Lordick F, et al. Incidence of gastric and gastro-esophageal cancer in the ToGA trial: correlation with HER2 positivity. Gastrointestinal Cancers Symposium. 2008: 75(Abstr 11).

Tateishi M, Toda T, Minamisono Y, et al. Clinicopathological significance of c-erbB-2 protein expression in human gastric carcinoma. Surg Oncol. 1992; 49:209–212. https://doi.org/10.1002/jso.2930490402

Sasano H, Date F, Imatani A, et al. Double immunostaining for c-erbB-2 and p53 in human stomach cancer cells. Hum Pathol. 1993; 24:584–9. https://doi.org/10.1016/0046-8177(93)90236-A

Uchino S, Tsuda H, Maruyama K, et al. Overexpression of c-erbB-2 protein in gastric cancer. Its correlation with long-term survival of patients. Cancer. 1993; 72:3179–184. https://doi.org/10.1002/1097-0142(19931201)72:11<3179::AID-CNCR2820721108>3.0.CO;2-#

Mizutani T, Onda M, Tokunaga A, et al. Relationship of c-erbB-2 protein expression and gene amplification to invasion and metastasis in human gastric cancer. Cancer. 1993; 72:2083–8. https://doi.org/10.1002/1097-0142(19931001)72:7<2083::AID-CNCR2820720705>3.0.CO;2-1

Nakajima M, Sawada H, Yamada Y, et al. The prognostic significance of amplification and overexpression of c-met and c-erbB-2 in human gastric carcinomas. Cancer. 1999; 85:1894–1902. https://doi.org/10.1002/(SICI)1097-0142(19990501)85:9<1894::AID-CNCR3>3.0.CO;2-J

Yamanaka S, Olaru AV, An F, et al. MicroRNA 21 inhibits Serpini1, a gene with novel tumour suppressive effects in gastric cancer. Dig Liver Dis. 2012; 44:589 96. https://doi.org/10.1016/j.dld.2012.02.016 PMid:22464652 PMCid:PMC3360813

Hudler P. Genetic aspects of gastric cancer instability. Scientific World Journal. 2012; 2012: 761909. https://doi.org/10.1100/2012/761909 PMid:22606061 PMCid:PMC3353315

Yasui W, Sumiyoshi H, Hata J, et al. Expression of epidermal growth factor receptor in human gastric and colonic carcinomas. Cancer Res. 1988; 48:137 41.

Sakai K, Mori S, Kawamoto T, et al. Expression of epidermal growth factor receptors on normal human gastric epithelia and gastric carcinomas. J Natl Cancer Inst. 1986; 77:1047 1052. PMid:3464796

Garcia I, Vizoso F, Martin A, et al. Clinical significance of the epidermal growth factor receptor and HER2 receptor in resectable gastric cancer. Ann Surg Oncol. 2003; 10:234 241. https://doi.org/10.1245/ASO.2003.05.010 PMid:12679307

Terashima M, Kitada K, Ochiai A, et al. ACTS GC Group: Impact of expression of human epidermal growth factor receptors EGFR and ERBB2 on survival in stage II/III gastric cancer. Clin Cancer Res. 2012; 18:5992 6000. https://doi.org/10.1158/1078-0432.CCR-12-1318 PMid:22977193

Kono K, Takahashi A, Sugai H, at al. Dendritic Cells Pulsed with HER-2/neu-derived Peptides Can Induce Specific T-Cell Responses in Patients with Gastric Cancer. Clin Cancer Res. 2002; 8:3394–400. PMid:12429626

Kim JY, Jeon TJ, Bae BN, et al. The prognostic significance of growth factors and growth factor receptors in gastric adenocar¬cinoma. APMIS. 2013; 121:95 104. https://doi.org/10.1111/j.1600-0463.2012.02942.x PMid:23030255

Hofmann M, Stoss O, Shi D, et al. Assessment of a HER2 scoring system for gastric cancer: results from a validation study. Histopathology. 2008; 52(7):797-805. https://doi.org/10.1111/j.1365-2559.2008.03028.x PMid:18422971

Mitri Z, Constantine T, O'Regan R. The HER2 Receptor in Breast Cancer: Pathophysiology, Clinical Use, and New Advances in Therapy. Chemother Res Pract. 2012; 2012:743193. https://doi.org/10.1155/2012/743193

Reichelt U, Duesedau P, Tsourlakis MCh, et al. Frequent homogenous HER-2 amplification in primary and metastatic adenocarcinomas of the esophagus. Mod Path. 2007; 20(1):120–129. https://doi.org/10.1038/modpathol.3800712 PMid:17143264

Gravalos C, Marquez A, Garcia-Carbonero R, et al. Correlation between Her2/neu overexpression/amplification and clinicopathological parameters in advanced gastric cancer patients: a prospective study. Gastrointestinal Cancers Symposium, 2007:130 (Abstr 89).

Fujimoto-Ouci K, Sekiguchi F, Yasuno H, Moriya Y, Moti K, Tanaka Y. Antitumor activity of transtuzumab in combination with chemotherapy in human gastric cancer xenograft models. Cancer Chemotherapy and Pharmacology. 2007; 59(6):795-805. https://doi.org/10.1007/s00280-006-0337-z PMid:17031648

Zuo Q, Liu J, Zhang J, Wu M, Guo L, Liao W. Development of trastuzumab-resistant human gastric carcinoma cell lines and mechanisms of drug resistance. Scientific reports. 2015; 5:11634. https://doi.org/10.1038/srep11634 PMid:26108989 PMCid:PMC4479993

Published
2018-06-30
How to Cite
1.
Ognjenovikj L, Trajkovski G, Gjoshev S, Shumkovski A, Dzambaz D, Hadzi-Manchev D, Volcevski G, Fildishevski I, Nikolova D, Petrushevska G, Janevska V, Janevski V. HER2 Positive Gastric Carcinomas and Their Clinico-Pathological Characteristics. Open Access Maced J Med Sci [Internet]. 2018Jun.30 [cited 2020Nov.27];6(7):1187-92. Available from: https://www.id-press.eu/mjms/article/view/oamjms.2018.280
Section
A - Basic Science

Most read articles by the same author(s)